Pharmacopeia — Technical Presentation (May 2008)
4 slides from Pharmacopeia's technical presentation, May 16, 2008
Slide 1: Abstract and Background: PS433540 dual-acting receptor antagonist
ABSTRACT PS433540 is a novel, first-in-class, dual-acting receptor antagonist (DARA) that potently blocks the angiotensin-1 (AT1) and endothelin receptor type A (ETA) receptors. A double-blind, randomized, placebo-controlled, ascending multipledose study in healthy subjects was conducted to evaluate
Slide 2: Methods and Results: Study Design and Subject Disposition
METHODS Study Design: Single-center, randomized, double-blind, placebo-controlled, multiple-ascending dose study; Study consisted of 5 cohorts of 8 subjects each (40 subjects total); Within each cohort, the subjects were randomized and 6 subjects received PS433540, and 2 subjects received placebo; U
Slide 3: Plasma PS433540 Concentration, AUC versus Dose, and PK Parameters
Figure 2. Mean Plasma PS433540 Concentration vs Time on Day 1 (A) and Day 14 or 15 (B) I I I I I I I I I I I I I I 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Hours from Dosing 8000 - 7000 - 6000 - 5000 - 4000 - 3000 - 2000 - 1000 - 0 - Plasma PS433540 Concentration (ng/mL) 50 mg PS433540 100 mg PS433540
Slide 4: Plasma Renin Activity, Blood Pressure and Safety
Figure 4. Plasma Renin Activity 0 2 4 8 12 24 0 2 4 8 12 24 Hours Hours Day 1 Day 15 25 - 15 - 5 - -5 - Absolute Change From Baseline (ng/mL/h) Placebo PS433540 100 mg PS433540 250 mg PS433540 500 mg PS433540 1000 mg # P vs placebo <0.0001 * P vs placebo <0.005 ** P vs placebo <0.05 Figure 5. Supine